Rockwell Medical Announces Executive and Board Changes
Ticker: RMTI · Form: 8-K · Filed: Nov 18, 2025 · CIK: 1041024
| Field | Detail |
|---|---|
| Company | Rockwell Medical, Inc. (RMTI) |
| Form Type | 8-K |
| Filed Date | Nov 18, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $45,000, $5,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
TL;DR
Rockwell Medical shakes up leadership, new execs and directors appointed.
AI Summary
On November 17, 2025, Rockwell Medical, Inc. announced changes in its executive team and board of directors. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key executives.
Why It Matters
Changes in leadership and board composition can signal shifts in company strategy, operational focus, or financial direction.
Risk Assessment
Risk Level: medium — Executive and board changes can introduce uncertainty regarding future strategy and performance.
Key Players & Entities
- Rockwell Medical, Inc. (company) — Registrant
- November 17, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 30142 S. Wixom Road (address) — Business address
- Wixom (city) — Business city
FAQ
What specific roles have been affected by the executive and director changes?
The filing indicates the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for certain officers, but does not specify the exact roles affected in this summary.
When did the reported changes take effect?
The earliest event reported in this filing occurred on November 17, 2025.
What is Rockwell Medical, Inc.'s state of incorporation?
Rockwell Medical, Inc. is incorporated in Delaware.
What is the primary business address of Rockwell Medical, Inc.?
The primary business address is 30142 S. Wixom Road, Wixom, MI 48393.
Are there any details on new compensatory arrangements for officers?
The filing mentions updates to compensatory arrangements of certain officers, but the specific details of these arrangements are not provided in the summary.
Filing Stats: 763 words · 3 min read · ~3 pages · Grade level 11.1 · Accepted 2025-11-18 07:30:30
Key Financial Figures
- $0.0001 — h registered Common Stock, par value $0.0001 RMTI Nasdaq Capital Market Indicate
- $45,000 — will receive an annual cash retainer of $45,000 for his service as a director and $5,00
- $5,000 — 5,000 for his service as a director and $5,000 for service on the Nominating Committee
Filing Documents
- tm2531538d1_8k.htm (8-K) — 26KB
- 0001104659-25-113452.txt ( ) — 186KB
- rmti-20251117.xsd (EX-101.SCH) — 3KB
- rmti-20251117_lab.xml (EX-101.LAB) — 33KB
- rmti-20251117_pre.xml (EX-101.PRE) — 22KB
- tm2531538d1_8k_htm.xml (XML) — 3KB
02 Departure of Directors or Certain Officers; Election
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 17, 2025, Andrea Heslin Smiley resigned from the Board of Directors (the "Board") of Rockwell Medical, Inc. (the "Company") and all Board committees on which she served, effective immediately. Ms. Smiley's resignation was not the result of any disagreement between Ms. Smiley and the Company on any matter relating to the Company's operations, policies or practices. On November 17, 2025, the Board appointed Joseph H. Dawson to the Board as a Class II director to serve until the Company's 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective immediately. Mr. Dawson has also been appointed to serve on the Nominating and Corporate Governance Committee of the Board (the "Nominating Committee"), effective immediately. Mr. Dawson, aged 60, currently serves as an independent consultant. From May 2013 to June 2025, he served as President, North America of Nipro Medical Corporation. Prior to that, Mr. Dawson served as Senior Director of Corporate Account Sales for Cordis Corporation, then a subsidiary of Johnson & Johnson. Mr. Dawson earned his Bachelor of Science in Neurobiology from St. John's University. In accordance with the Company's non-employee director compensation policy, Mr. Dawson will receive an annual cash retainer of $45,000 for his service as a director and $5,000 for service on the Nominating Committee, which will be pro-rated through the Company's 2026 Annual Meeting of Stockholders. In addition, Mr. Dawson was granted an option to purchase 25,000 shares of the Company's common stock at an exercise price equal to the closing price of the Company's common stock on The Nasdaq Capital Market on November 17, 2025, and 25,000 restricted stock units for his service as a director. The equity awards were made under the Company's Amended and Restated